Medicine and Dentistry
Endoscopic Ultrasound
100%
Hepatocellular Carcinoma
47%
Chronic Pancreatitis
34%
Bevacizumab
33%
Atezolizumab
33%
Neoplasm
32%
Diagnosis of Chronic Pancreatitis
31%
Elastography
31%
Cystic Pancreatic Lesion
31%
Diagnosis
28%
Intraductal Papillary Mucinous Tumor
28%
Diseases
25%
Endoscopic Retrograde Cholangiopancreatography
24%
Autoimmune Pancreatitis
22%
Adverse Event
22%
Pancreas Disease
21%
Retrospective Study
21%
Fine-Needle Aspiration
20%
Adenoma
20%
Adenocarcinoma
20%
Shear Wave Elastography
20%
Biopsy
19%
Pancreas Tumor
19%
Cholangiocarcinoma
19%
Immune Checkpoint Inhibitor
19%
Endoscopic Papillotomy
18%
Bile Duct
17%
Endoscopic Ultrasound Guided Fine Needle Biopsy
15%
Polyp
15%
Cholangitis
15%
Quantitative Diagnosis
15%
Cholestasis
15%
Liver Surgery
15%
Common Bile Duct
15%
Synapsin II
15%
Reproducibility
15%
Somatomedin B
15%
Combination Therapy
15%
Ultrasonography
15%
Contrast-Enhanced Ultrasound
15%
Tumor Gene
15%
Metabolic Dysfunction-Associated Steatohepatitis
15%
Cabozantinib
15%
Des-Gamma Carboxyprothrombin
15%
Biological Marker
15%
Treatment Response
15%
Alpha-Fetoprotein
15%
Sphincter
13%
Bleeding
11%
Papilloma
11%
Keyphrases
Atezolizumab Plus Bevacizumab
47%
Endoscopic Ultrasonography
34%
Advanced Hepatocellular Carcinoma
31%
Intraductal Papillary mucinous Neoplasm
28%
Chronic Pancreatitis
25%
Display Method
15%
Medical Ultrasonics
15%
Efficacy Predictor
15%
Transabdominal
15%
Quantitative Diagnosis
15%
Shear Wave Elastography
15%
Hydrogen Concentration
15%
Ultrasonographic Elastography
15%
Breath Hydrogen
15%
Franseen Needle
15%
Ampullary Adenoma
15%
Pancreatic Neoplasms
15%
Shear Wave Velocity Prediction
15%
Elastography
15%
Contrast-enhanced Harmonic Endoscopic Ultrasonography
15%
Pancreatic Cyst
15%
Ultrasonographic Diagnosis
15%
Tumor Assessment
15%
Endoscopic Ultrasound
15%
Complete Response
15%
Clinical Practice
15%
Tremelimumab
15%
Combination Therapy
15%
Cancer Gene Panel Testing
15%
Metabolic Dysfunction-associated Steatohepatitis
15%
Function Composition
15%
Elastic Modulus
13%
Normal Pancreas
13%
Atezolizumab
13%
Lenvatinib
12%
Mural Nodule
12%
Bevacizumab
11%
Ultrasound B-mode
10%
Article Use
7%
Bile Duct Tumor
7%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
7%
Autoimmune Pancreatitis
6%
Vascular Function
6%
Affecting Factors
6%
Contrast-enhanced Harmonic EUS
6%
Adverse Events
6%
High Spatial Resolution
5%
Clot
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
79%
Bevacizumab
65%
Atezolizumab
65%
Diseases
37%
Alpha Fetoprotein
31%
Immune Checkpoint Inhibitor
19%
Adverse Event
18%
Combination Therapy
17%
Solid Malignant Neoplasm
17%
Pancreas Disease
15%
Tremelimumab
15%
Pancreas Duct Stenosis
15%
Adenoma
15%
Adenocarcinoma
15%
Cabozantinib
15%
Biological Marker
15%
Decarboxyprothrombin
15%
Lenvatinib
14%
Disease
14%
Bleeding
11%
Progression Free Survival
11%
Recurrent Disease
9%
Remission
9%
Pancreatitis
6%
Overall Survival
5%
Retrospective Study
5%
